MARKET

ALXO

ALXO

Alx Oncology Holdings Inc
NASDAQ
1.060
+0.040
+3.92%
After Hours: 1.060 0 0.00% 19:30 11/20 EST
OPEN
1.010
PREV CLOSE
1.020
HIGH
1.110
LOW
0.9802
VOLUME
997.71K
TURNOVER
--
52 WEEK HIGH
2.660
52 WEEK LOW
0.8617
MARKET CAP
137.03M
P/E (TTM)
-1.2048
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Veeva Systems (VEEV), ALX Oncology Holdings (ALXO)
TipRanks · 4d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 4d ago
Alx Oncology Warns Trial Enrollment Challenges Could Delay or Derail Evorpacept and ALX2004 Approvals
TipRanks · 4d ago
ALX Oncology Holdings Inc. Reports Third Quarter 2026 Financial Results
NASDAQ · 5d ago
ALX Oncology Holdings Q3 Adj. EPS $(0.13) Beats $(0.14) Estimate
Benzinga · 5d ago
ALX Oncology GAAP EPS of -$0.15 misses by $0.02
Seeking Alpha · 5d ago
*ALX Oncology 3Q Loss/Shr 15c >ALXO
Dow Jones · 5d ago
Press Release: ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 5d ago
More
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.

Webull offers ALX Oncology Holdings Inc stock information, including NASDAQ: ALXO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALXO stock methods without spending real money on the virtual paper trading platform.